Medicine and Dentistry
Adult
13%
Age
26%
Association
19%
Body Mass Index
11%
Childhood
11%
Cohort Analysis
19%
Colorectal Cancer
8%
Combination Therapy
18%
Corticosteroid
6%
COVID-19
6%
Crohn's Disease
39%
Development
7%
Diagnosis
23%
Diseases
12%
Family
10%
Follow up
8%
Hazard Ratio
26%
Health
10%
Incidence
28%
Infection
8%
Inflammatory Bowel Disease
27%
Infliximab
6%
Inpatient
23%
Lesion
8%
Life
10%
Malignant Neoplasm
7%
Man
6%
Maturity Onset Diabetes of the Young
14%
Mercaptopurine
15%
Mesalazine
9%
Meta-Analysis
11%
Necrosis
8%
Obesity
8%
Odds Ratio
15%
Patient
53%
Patient with Crohn's Disease
16%
Patient with Inflammatory Bowel Disease
51%
Patient with Ulcerative Colitis
17%
Person
16%
Prevalence
8%
Proportional Hazards Model
7%
Sex
11%
Standardized Incidence Ratio
6%
Surgery
9%
Surveillance
7%
Systematic Review
6%
Therapeutic Procedure
18%
Tumor Necrosis Factor
18%
Ulcerative Colitis
32%
Woman
6%
Nursing and Health Professions
Appendicitis
5%
Cohort Analysis
8%
Combination Therapy
5%
Confidence Interval
15%
Crohn Disease
18%
Diagnosis
18%
Diseases
7%
Eosinophilic Esophagitis
5%
Hospital
5%
Hospitalization
5%
Incidence
13%
Inflammatory Bowel Disease
59%
Inpatient
21%
Malignant Neoplasm
6%
Meta Analysis
9%
Non Insulin Dependent Diabetes Mellitus
5%
Patient
27%
Patient with Crohn's Disease
11%
Patient with Inflammatory Bowel Disease
13%
Patient with Ulcerative Colitis
15%
Prevalence
5%
Procedures
6%
Standardized Incidence Ratio
5%
Surgery
6%
Tumor Necrosis Factor
8%
Ulcerative Colitis
15%
Uterine Cervix Cancer
5%
Vedolizumab
5%
Woman
5%
Pharmacology, Toxicology and Pharmaceutical Science
Aminosalicylic Acid
9%
Antibiotics
6%
Appendicitis
7%
Corticosteroid
5%
Crohn Disease
27%
Diseases
10%
Eosinophilic Esophagitis
5%
Ileitis
5%
Incidence
23%
Infection
7%
Inflammatory Bowel Disease
100%
Infliximab
6%
Malignant Neoplasm
7%
Mercaptopurine
15%
Microscopic Colitis
5%
Necrosis
8%
Non Insulin Dependent Diabetes Mellitus
12%
Obesity
11%
Standardized Incidence Ratio
5%
Tumor Necrosis Factor
17%
Ulcerative Colitis
22%
Uterine Cervix Cancer
5%
Vedolizumab
5%